https://www.selleckchem.com/products/msa-2.html
To report efficacy and safety measures of the XEN45 gel stent at 36 months in the UK National Health Service setting. Retrospective non-comparative audit of the records of patients who underwent XEN45 implantation between June 2015 and May 2017 was performed. Main outcome measures were intraocular pressure and number of antihypertensive medications used. Failure was defined as need for further surgery or stent removal. Success was defined as a 20% decrease in intraocular pressure without the need for additional glaucoma medications or a r